FDA Approves First-in-Class Combo Drug for Heart Failure

A pill combining valsartan and sacubitril has received first-in-class approval for heart failure under the Food and Drug Administration's priority review program. Entresto offers practitioners a new option for reducing risk of cardiovascular death and hospitalization in patients with NYHA class II-IV heart failure and reduced ejection fraction.
Source: Caring for the Ages - Category: Health Management Authors: Source Type: news